Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Inclusion Criteria: * Age ≥ 18 years. * Signed informed consent * ECOG performance status: 0-2 * Histologically documented adenocarcinoma of the prostate * Progressive disease despite androgen deprivation therapy. Progressive disease is defined as any one of the following: * Measurable Disease: Objective evidence of increase \> 20% in the sum of the longest diameters of target lesions from the time of maximal regression or the appearance of one or more new lesions (Modified RECIST Criteria) * Bone Scan Progression: Appearance of one or more new lesions on bone scan attributable to prostate cancer * PSA Progression: An elevated PSA (≥ 5 ng/ml) which has risen serially from baseline on two occasions each at least one week apart * At least 4 weeks since any other hormonal therapy. Flutamide and megestrol acetate (any dose) must be discontinued at least 4 weeks prior to initiating treatment. Bicalutamide or nilutamide must be discontinued at least 6 weeks prior to initiating treatment. If improvement following antiandrogen withdrawal is noted, progression must be established using the criteria above. Androgen suppression should be continued * ≥ 4 weeks since major surgery and fully recovered * ≥ 8 weeks since high risk surgery and fully recovered * ≥ 4 weeks since any prior radiation and fully recovered * ≥ 6 weeks since the last dose of bone targeted radiopharmaceutical * Men of child-bearing potential are required to use an effective means of contraception * Required Initial Laboratory Values: * ANC ≥ 1500/µL * Platelet count ≥ 100,000/µL * Creatinine ≤ 1.5 x ULN * Bilirubin ≤ 1.5 x ULN * AST ≤ 1.5 x ULN * Urine protein to creatinine ratio \< 1.0 * Serum Testosterone ≤ 50 ng/dL (For patients who have not had bilateral orchiectomy.) Exclusion Criteria: * Prior treatment with cytotoxic chemotherapy for metastatic disease * Prior treatment with anti-angiogenic agents, including thalidomide and bevacizumab * Prior treatment with any investigational drug within 4 weeks of initiating treatment * Prior treatment with an mTor inhibitor * Chronic treatment with systemic steroids or another immunosuppressive agent * Known history of HIV seropositivity * Known brain metastases (brain imaging is not required) * Congestive heart failure * Uncontrolled hypertension. Patients with history of hypertension must be well controlled (\< 150/100) on a regimen of anti-hypertensive therapy * Any prior history of hypertensive crisis or hypertensive encephalopathy * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Active bleeding diathesis or on oral anti-vitamin K medications (except low dose coumarin) * Arterial thrombotic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), at any time * History of unstable angina or angina requiring surgical or medical intervention in the past 12 months, or myocardial infarction (MI) * Patients with clinically significant peripheral artery disease or any other arterial thrombotic event * Significant vascular disease * Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study * Proteinuria at screening as demonstrated by either * Urine protein:creatinine (UPC) ratio ≥ 1.0 OR * Urine dipstick for proteinuria ≥ 2+ * Serious or non-healing wound, ulcer or bone fracture * Peripheral neuropathy ≥ grade 2 * Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * Herbal medications and food supplements must be discontinued before registration. Patients may continue on daily vitamins and calcium supplements * History of noncompliance to medical regimens * Unwilling to or unable to comply with the protocol